CN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer

Lung Cancer

Volumn 49, Issue 3, 2005, Pages 363-370

  Sève, Pascal ^a,b,d   Mackey, John R ^b   Isaac, Sylvie ^c   Trédan, Olivier ^d   Souquet, Pierre Jean ^c   Pérol, Maurice ^e   Cass, Carol ^b   Dumontet, Charles ^d,f  

^a HÔTEL DIEU   (France)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CENTRE HOSPITALIER LYON SUD   (France)

^d INSERM   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Chemoresistance; Gemcitabine; High Km 5 nucleotidases (cN II); Human nucleotide equilibrative nucleoside transporter 1 (hENT1); Non small cell lung cancer (NSCLC)

Indexed keywords

5' NUCLEOTIDASE; 5' NUCLEOTIDASE CN II; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE KINASE; GEMCITABINE; HUMAN CONCENTRATIVE NUCLEOSIDE TRANSPORTER 3; HUMAN NUCLEOTIDE EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; NAVELBINE; NUCLEOSIDE TRANSPORTER; PACLITAXEL; PHOSPHOTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PARAMETER; PREDICTION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; STATISTICAL MODEL; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; WEIGHT REDUCTION;

5'-NUCLEOTIDASE; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 23744495336     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.04.008     Document Type: Article

References (30)

1. C. Galmarini, J. Mackey, and C. Dumontet Nucleoside analogues and nucleobases in cancer treatment Lancet Oncol 3 2002 415 424
2. D.G. Pfister, D.H. Johnson, C.G. Azzoli, W. Sause, T.J. Smith, and S. Baker American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
3. T. Le Chevalier, G. Scagliotti, R. Natale, S. Danson, R. Rosell, and R. Stahel Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes Lung Cancer 47 2005 69 80
4. A. Bergman, H. Pinedo, and G. Peters Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine) Drug Resist Updates 5 2002 19 33
5. C. Galmarini, J. Mackey, and C. Dumontet Nucleoside analogues: mechanisms of drug resistance and reversal strategies Leukemia 15 2001 875 890
6. M.W. Ritzel, A.M. Ng, S.Y. Yao, K. Graham, S.K. Loewen, and K.M. Smith Recent molecular advances in studies of the concentrative nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib) Mol Memb Biol 18 2001 65 72
7. J.L. Abbruzzese, R. Grunewald, E.A. Weeks, D. Gravel, T. Adams, and B. Nowak A phase I clinical, plasma, and cellular pharmacology study of gemcitabine J Clin Oncol 9 1991 491 498
8. W. Plunkett, P. Huang, Y.Z. Xu, V. Heinemann, R. Grunewald, and V. Gandhi Gemcitabine: metabolism, mechanisms of action, and self-potentiation Semin Oncol 22 1995 3 10
9. M. Schirmer, A.P. Stegmann, F. Geisen, and G. Konwalinka Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5′-nucleotidase activity Exp Hematol 26 1998 1223 1228
10. C. Dumontet, K. Fabianowska-Majewska, D. Mantincic, E. Callet Bauchu, I. Tigaud, and V. Gandhi Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562 Br J Haematol 106 1999 78 85
11. D.A. Carson, J. Kaye, S. Matsumoto, J.E. Seegmiller, and L. Thompson Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines Proc Natl Acad Sci USA 76 1979 2430 2433
12. C. Galmarini, X. Thomas, K. Graham, A. El Jafaari, E. Cros, and L. Jordheim Deoxycitidine kinase and CN-II nucleotidase expression in blast predict survival in acute myeloid leukaemia patients treated with cytarabine Br J Haematol 122 2003 53 60
13. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, and W. Plunkett Action of 2′,2′-difluorodeoxycytidine on DNA synthesis Cancer Res 51 1991 6110 6117
14. P. Huang, and W. Plunkett Induction of apoptosis by gemcitabine Semin Oncol 22 1995 19 25
15. V.W.T. Ruiz van Haperen, G. Veerman, C.J.A. Van Moorsel, and G.J. Peters Induction of in vivo resistance against gemcitabine (dFdC, 2′,2′- difluoro-deoxycytidine) Adv Exp Med Biol 431 1998 637 640
16. R. Rosell, G. Scagliotti, K.D. Danenberg, Lord RVN, G. Bepler, and S. Novello Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell Oncogene 22 2003 3548 3553
17. R. Rosell, K.D. Danenberg, V. Alberola, R. Bepler, J.J. Sanchez, and C. Camps Spanish Lung Cancer Group. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients Clin Cancer Res 10 2004 1318 1325
18. R. Rosell, E. Felip, M. Taron, J. Majo, P. Mendrez, and M. Sanchez-Ronco Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery Clin Cancer Res 10 2004 4215s 4219s
19. J.R. Mackey, L.L. Jennings, M.L. Clarke, C.L. Santos, L. Dabbagh, and M. Vsianska Immunohistochemical variation of human equilibrative nucleoside transporter 1 in primary breast cancer Clin Cancer Res 8 2002 110 116
20. J. Spratlin, R. Sangha, D. Glubrecht, L. Dabbagh, J.D. Young, and C. Dumontet The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma Clin Cancer Res 10 2004 6956 6961
21. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717
22. A.B. Miller, B. Hoogstraten, Staquet, and A. Winkler Reporting results of cancer treatment Cancer (Phila) 47 1981 207 214
23. P. Hatzis, A.S. Al-Madhoon, M. Jullig, T.G. Petrakis, S. Eriksson, and I. Talianidis The intracellular localization of deoxycytidine kinase J Biol Chem 273 1998 30239 30243
24. J.R. Mackey, R.S. Mani, M. Selner, D. Mowles, J.D. Young, and J.A. Belt Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines Cancer Res 58 1998 4349 4357
25. C. Mazzon, C. Rampazzo, M.C. Scaini, L. Gallinaro, A. Karlsson, and C. Meier Cytosolic and mitochondrial deoxyribonucleotidases: activity with substrate analogs, inhibitors and implications for therapy Biochem Pharmacol 66 2003 471 479
26. C.M. Galmarini, K. Graham, X. Thomas, F. Calvo, P. Rousselot, and A. El Jafaari Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia Blood 98 2001 1922 1926
27. R. Rosell, M. Taron, A. Barnadas, G. Scagliotti, C. Sarries, and B. Roig Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer Cancer Control 10 2003 297 305
28. C. Camps, C. Sarries, B. Roig, J.J. Sanchez, C. Queralt, and E. Sancho Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients Clin Lung Cancer 4 2003 237 241
29. D. Isla, C. Sarries, R. Rosell, G. Alonso, M. Domine, and M. Taron Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer Ann Oncol 15 2004 1194 1203
30. A. Font, J.M. Sanchez, M. Taron, E. Martinez-Balibrea, J.J. Sanchez, and J.L. Manzano Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism Invest New Drugs 21 2003 435 443